Aviva’s Prothena Corp PRTA Stock Holding History

Aviva’s Portfolio PRTA Stock Details PRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,595	Closed	-$770K	–	1096
2021 Q4	$770K	Buy	+15,595	New	+$865K	﹤0.01%	957

Other funds holding PRTA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aviva's PRTA Position: Q1 2022 in Review

Aviva sold out of Prothena Corp (PRTA) in Q1 2022, closing a stake of 15,595 shares — an estimated $770K sold.

Aviva first reported a position in PRTA in Q4 2021 and held it in 1 quarter. The position peaked at $770K in Q4 2021. 174 funds tracked by Wall St. Rank hold PRTA as of Q1 2022.

Aviva reported no remaining Prothena Corp position as of Q1 2022 after selling out during the quarter.
Aviva sold 15,595 Prothena Corp shares in Q1 2022, an estimated $770K.
Aviva first reported a position in Prothena Corp in Q4 2021 and held it in 1 quarter.
Aviva's Prothena Corp position peaked at $770K in Q4 2021.
174 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2022.

Based on Aviva's 13F filing for Q1 2022, filed 13 May 2022.